Our Pricing

Change Mounjaro to Wegovy: UK Clinical Comparison & Switching Guide

Many UK patients consider whether to change Mounjaro to Wegovy after starting their weight loss journey, often due to cost differences, side effect profiles, or availability concerns. Both tirzepatide (Mounjaro) and semaglutide (Wegovy) are highly effective GLP-1 receptor agonists licensed by the MHRA for chronic weight management, but they work through distinct mechanisms and require different dosing protocols when transitioning between treatments. This guide provides evidence-based insights from our UK clinical team to help you understand the practical considerations, safety requirements, and expected outcomes when switching from Mounjaro to Wegovy under prescriber supervision.

Why UK Patients Change Mounjaro to Wegovy

The decision to change Mounjaro to Wegovy typically stems from three main factors: cost considerations, tolerability differences, or supply availability. Wegovy is priced from £124.99 at Cured Pharmacy compared to Mounjaro at £124.99, representing a significant monthly saving for long-term treatment [1]. While both medications deliver substantial weight loss, some patients experience better gastrointestinal tolerance with semaglutide's single GLP-1 receptor action compared to tirzepatide's dual GIP/GLP-1 mechanism.

Clinical experience shows that patients who have achieved their initial weight loss targets on Mounjaro may successfully transition to Wegovy for maintenance therapy, particularly when cost becomes a priority consideration. The STEP clinical trial programme demonstrated that semaglutide 2.4mg delivered average weight reductions of 15-17% from baseline over 68 weeks, while SURPASS trials showed tirzepatide achieving 15-22% reductions depending on dose [2]. Both remain highly effective options, and switching between them is clinically appropriate when supervised by a UK prescriber who can tailor the transition protocol to your individual response and medical history.

Cost Comparison for Long-Term Treatment

For patients committed to 12-month weight management programmes, the cumulative cost difference between Mounjaro and Wegovy becomes substantial. At Cured Pharmacy's transparent pricing, a full year of Wegovy treatment costs approximately £124.99 compared to £124.99 for Mounjaro, saving over £124.99 annually. These figures assume maintenance dosing and do not account for the £20 discount available with code Weightlossnew on your first order, which further reduces initial costs. All prices are shown upfront before consultation, ensuring you can make informed financial decisions about your weight loss journey.

How to Safely Change Mounjaro to Wegovy: Dosing Protocol

When you change Mounjaro to Wegovy, your prescriber will determine the appropriate starting dose based on your current tirzepatide dose and treatment duration. The standard approach involves a washout consideration due to differing half-lives: tirzepatide has a half-life of approximately 5 days, while semaglutide's is around 7 days [3]. Most UK prescribers recommend starting Wegovy at 0.25mg weekly after your final Mounjaro dose, even if you were on a higher tirzepatide maintenance dose, to minimise gastrointestinal side effects during the transition period.

The Wegovy dose escalation schedule then follows the licensed protocol: 0.25mg weekly for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, and finally 2.4mg as the maintenance dose [4]. This gradual titration is essential for tolerability, regardless of your previous Mounjaro dose. Some patients who were well-established on Mounjaro 10mg or 15mg may progress through the Wegovy escalation slightly faster under close prescriber supervision, but this must be individualised based on your response and side effect profile. Never adjust dosing schedules without consulting your prescriber, as both medications require careful clinical monitoring throughout any transition.

Efficacy Differences When You Change Mounjaro to Wegovy

Patients often ask whether they will maintain their weight loss results after changing Mounjaro to Wegovy, and clinical evidence suggests that semaglutide provides robust weight maintenance when used at the full 2.4mg dose. Head-to-head trial data from SURPASS-2 showed tirzepatide delivered slightly greater weight reductions than semaglutide 1mg (not the 2.4mg Wegovy dose), but real-world UK clinical experience demonstrates that patients who switch to Wegovy typically maintain their achieved weight loss provided they adhere to the full maintenance dose and continue lifestyle modifications [5].

The key difference lies in the mechanism: Mounjaro's dual GIP/GLP-1 receptor agonism may produce marginally greater peak weight loss in some individuals, while Wegovy's selective GLP-1 action still delivers clinically significant results with a well-established safety profile across diverse patient populations. If you experienced a plateau on Mounjaro, switching to Wegovy is unlikely to break that plateau unless combined with renewed dietary and activity interventions. Conversely, if cost or side effects were limiting your Mounjaro adherence, transitioning to Wegovy may actually improve long-term outcomes by supporting consistent weekly dosing. Your prescriber will assess your individual weight loss trajectory and metabolic response when recommending whether to change Mounjaro to Wegovy.

Expected Weight Loss Trajectory After Switching

Most patients who change Mounjaro to Wegovy experience stable weight maintenance during the transition period, with some continuing gradual loss as they titrate up to the full 2.4mg semaglutide dose. Clinical observations suggest that patients who achieved 10-15% body weight reduction on Mounjaro maintain those results on Wegovy, with an additional 2-5% loss possible if they were not yet at their weight loss plateau. The critical factor is completing the full Wegovy dose escalation to 2.4mg weekly, as lower doses may not provide equivalent appetite suppression and metabolic benefits to higher-dose tirzepatide regimens.

Side Effects to Expect When Changing Mounjaro to Wegovy

The side effect profile differs subtly when you change Mounjaro to Wegovy, primarily due to the shift from dual GIP/GLP-1 agonism to selective GLP-1 receptor activation. Common gastrointestinal effects—nausea, diarrhoea, constipation, and abdominal discomfort—occur with both medications, but clinical experience shows that some patients who experienced persistent nausea on Mounjaro find semaglutide better tolerated, while others report the opposite [6]. Starting Wegovy at the lowest 0.25mg dose and following the gradual escalation protocol significantly reduces the intensity of these effects during transition.

Rare but serious side effects, including pancreatitis risk, thyroid C-cell tumour warnings, and gallbladder complications, apply equally to both tirzepatide and semaglutide, as these are class effects of GLP-1 receptor agonists. Your prescriber will review your complete medical history before approving the switch, particularly if you experienced any adverse events on Mounjaro. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use either medication. If you discontinued Mounjaro due to intolerable side effects rather than cost or availability, discuss alternative weight management options with your UK clinical team, as Wegovy may produce similar reactions given the overlapping mechanism of action.

Prescription Process to Change Mounjaro to Wegovy at Cured Pharmacy

Changing Mounjaro to Wegovy requires a new clinical assessment by a UK-registered prescriber, even if you have an active Mounjaro prescription. At Cured Pharmacy, the process takes under 3 minutes: complete the online consultation form detailing your current tirzepatide dose, treatment duration, weight loss achieved, and any side effects experienced. Our clinical team, supervised by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), will review your medical history and current medications to confirm suitability for semaglutide and determine the appropriate starting dose.

Once approved, your Wegovy prescription is dispensed from our GPhC-registered pharmacy (9012511) with discreet next-day delivery across the UK. Pricing is fully transparent before you begin the consultation: Wegovy starts from £124.99, with an additional £20 off your first order using code Weightlossnew. All Wegovy supplied by Cured Pharmacy is genuine UK-licensed medication sourced through regulated channels and stored under controlled pharmaceutical conditions. Your prescriber will provide guidance on timing your first Wegovy dose relative to your last Mounjaro injection, typically recommending you begin the 0.25mg starter dose one week after your final tirzepatide injection to maintain therapeutic continuity while minimising overlapping drug exposure.

Ongoing Monitoring After You Change Mounjaro to Wegovy

Successful long-term weight management with Wegovy requires regular clinical monitoring, just as it did with Mounjaro. Your prescriber will schedule follow-up assessments every 4-12 weeks during the dose escalation phase to evaluate weight loss progress, tolerability, and any emerging side effects. Blood pressure, heart rate, and HbA1c monitoring (if you have type 2 diabetes) continue as part of comprehensive metabolic care. If you do not achieve at least 5% weight loss after 3-6 months on the full 2.4mg Wegovy dose, your prescriber will reassess whether continued semaglutide therapy is appropriate or whether alternative interventions should be considered, in line with NICE guidance on GLP-1 agonist use for weight management [7].

Cost Savings and UK Availability When You Change Mounjaro to Wegovy

Beyond the per-dose price advantage, changing Mounjaro to Wegovy can improve treatment accessibility during periods of supply constraint. Wegovy has experienced intermittent availability challenges across UK pharmacies, but Cured Pharmacy maintains direct relationships with licensed wholesalers to secure consistent stock for our patients. Our transparent pricing model ensures you always know the exact cost before starting treatment: £124.99 for Wegovy compared to £124.99 for Mounjaro, with no hidden fees or post-consultation price increases.

For patients funding their own weight loss treatment, this £124.99 monthly saving accumulates to over £124.99 annually, making long-term adherence more financially sustainable. The £20 discount available with code Weightlossnew on your first order further reduces the initial cost barrier when you change Mounjaro to Wegovy. Both medications require the same weekly injection commitment and similar lifestyle modification support, so switching based on cost does not compromise the behavioural components of your weight management programme. Our UK clinical team remains available throughout your treatment journey to support dose adjustments, manage side effects, and optimise your individual response to semaglutide therapy.

Insurance and NHS Prescribing Considerations

NHS prescribing of both Mounjaro and Wegovy for weight management remains highly restricted, with access typically limited to specialist weight management services under strict eligibility criteria. Most UK patients fund their GLP-1 agonist treatment privately, making the cost difference between tirzepatide and semaglutide a significant practical consideration. If you were initially prescribed Mounjaro through the NHS or a specialist clinic and wish to change Mounjaro to Wegovy via private prescription, ensure your current prescriber is informed of the switch to maintain continuity of care and avoid duplicate prescribing. Cured Pharmacy's clinical team can coordinate with your NHS GP or specialist to ensure seamless transition and appropriate shared-care arrangements where applicable.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., ... & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Urva, S., Quinlan, T., Landry, J., Coskun, T., Haupt, A., & Robins, D. (2021). Effects of renal impairment on the pharmacokinetics of tirzepatide. Clinical Pharmacokinetics, 60(9), 1049-1059. [accessed 15 August 2026]
4. Novo Nordisk. (2023). Wegovy (semaglutide) 2.4 mg Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
5. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
6. Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in Endocrinology, 12, 645563. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.